Viewpoint: China has the upper hand in cancer cell therapy – Boston Business Journal
Boston Business Journal |
Viewpoint: China has the upper hand in cancer cell therapy
Boston Business Journal Cheers went up last August when the U.S. Food and Drug Administration approved the world's first CAR–T cancer cell treatment, Novartis' Kymriah, and again in October when it approved Gilead's CAR–T treatment for non-Hodgkin's lymphoma. In CAR–T … |
